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Abstract
Background: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is an environmental contaminant that elicits a broad
spectrum of toxic effects in a species-specific manner. Current risk assessment practices routinely extrapolate results
from in vivo and in vitro rodent models to assess human risk. In order to further investigate the species-specific
responses elicited by TCDD, temporal gene expression responses in human HepG2, mouse Hepa1c1c7 and rat
H4IIE cells were compared.
Results: Microarray analysis identified a core set of conserved gene expression responses across species consistent
with the role of AhR in mediating adaptive metabolic responses. However, significant species-specific as well as
species-divergent responses were identified. Computational analysis of the regulatory regions of species-specific
and -divergent responses suggests that dioxin response elements (DREs) are involved. These results are consistent
with in vivo rat vs. mouse species-specific differential gene expression, and more comprehensive comparative DRE
searches.
Conclusions: Comparative analysis of human HepG2, mouse Hepa1c1c7 and rat H4IIE TCDD-elicited gene
expression responses is consistent with in vivo rat-mouse comparative gene expression studies, and more
comprehensive comparative DRE searches, suggesting that AhR-mediated gene expression is species-specific.
Background
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a ubiqui-
tous environmental contaminant that elicits a broad
spectrum of biochemical and physiological effects in a
species-specific manner [1]. These effects include lethal-
ity, cancer, developmental abnormalities, immunotoxi-
city, skin lesions, hepatotoxicity, and xenobiotic enzyme
metabolism induction. They result from altered gene
expression mediated by the aryl hydrocarbon receptor
(AhR), a ligand activated transcription factor [1,2].
Briefly, TCDD binds to the cytoplasmic AhR causing
nuclear translocation and heterodimerization with the
AhR nuclear translocator (ARNT). The heterodimer
then binds to specific DNA elements, termed dioxin
response elements (DREs), within the regulatory regions
of targeted genes to modulate expression, resulting in
downstream physiological responses [3]. Although the
structure and function of the AhR are highly conserved
[4], the sensitivity to and the responses elicited by
TCDD vary widely across species, suggesting TCDD and
related compounds may activate species-specific AhR-
mediated gene expression networks.
Risk assessment assumes that there is a conserved
mode of action and comparable toxic responses between
species. However, there are inherent differences between
species that compromise the extrapolation of rodent
data to estimate potential human risks. Moreover, there
is a discord between preclinical animal testing compared
to human clinical trials regarding toxicity [5]. Similarly,
species differ widely in response to TCDD exposure. For
example, LD50 values range from 1 μg/kg in the guinea
pig [6] to >1000 μg/kg for the hamster, and several
responses exhibit species-specific sensitivities and toxici-
ties. These differential effects are not attributed to dif-
ferences in binding affinity or AhR complex stability
[7-9]. Collectively, these data suggest that although the
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expression responses are species-specific.
To further investigate differences in TCDD elicited
differential gene expression, global gene expression was
assessed in human HepG2, mouse Hepa1c1c7 and rat
H4IIE hepatoma cells following treatment with TCDD.
Comparative analysis indicates there are significant dif-
ferences in gene expression between species, suggesting
AhR-mediated gene expression may not be conserved.
Results
Temporally Conserved Gene Expression Responses
Elicited by TCDD
Species-specific, cDNA microarrays were used to profile
the temporal gene expression elicited by TCDD in
human HepG2, mouse Hepa1c1c7 and rat H4IIE cells.
The microarrays queried 6995, 8478 and 5169 unique
human, mouse and rat genes, respectively (Table 1).
Empirical Bayes analysis identified 691, 439 and 57 dif-
ferentially expressed genes (P1(t) > 0.999 and |fold
change| > 1.4) in HepG2, Hepa1c1c7 and H4IIE cells,
respectively. Complete cDNA microarray data sets are
provided in Additional files 1, 2, 3. HepG2 cells were
the most responsive as indicated by both the overall
number of differentially expressed genes as well as the
number of responsive genes at each time point (Figure
1). H4IIE cells exhibited significantly less differentially
expressed genes, partially explained by the smaller
microarray and the immaturity of rat genome annota-
tion compared to the human and mouse. Differentially
expressed genes were hierarchically clustered based on
Euclidian distance and distinct clusters of temporal gene
expression patterns were identified (Figure 2).
Pair-wise comparisons of differentially expressed genes
were conducted using HomoloGene (build 35) defined
orthologs (Figure 3A). Human and mouse cDNA micro-
arrays shared 4546 orthologous genes, however only
0.9% (41 orthologs; Additional file 4) were differentially
regulated by TCDD in HepG2 and Hepa1c1c7 cells.
Comparison of the rodent platforms identified 3850
orthologs with only 0.2% (8 orthologs; Additional file 5)
responding in both Hepa1c1c7 and H4IIE cells. The
lack of conserved ortholog differential expression in
Hepa1c1c7 and H4IIE cells is consistent with the
reported differences in differential expression observed
in vivo between mice and rats [10-12]. Time dependent
profiling of HepG2 and H4IIE gene expression identified
only 5 conserved responses out of 2625 possible ortho-
logs, representing only 0.2% (Additional file 6). Com-
parative analysis across all three species with 2252
shared orthologous probes identified only one ortholog
that was differentially regulated in all three cell lines
(immediate early response 3, IER3; HomoloGene ID
2894). Note that other members of the AhR gene bat-
tery, namely CYP1A1, ALDH3A1 and NQO1, were not
present across all of the cDNA microarray platforms.
However, their responses were also conserved across all
three cell lines when measured using QRTPCR. The
results for CYP1A1 are shown in Figure 4.
Identification of Putative Primary Gene Expression
Responses
In order to further investigate AhR-mediated responses,
TCDD-elicited differential gene expression was exam-
ined in the presence of cycloheximide (CHX), a protein
translation inhibitor. Putative primary responses were
defined in this study as those where CHX co-treatment
either maintained or enhanced the response elicited by
Table 1 Gene coverage of species-specific cDNA microarray platforms and number of differentially regulated genes
Human HepG2 Mouse Hepa1c1c7 Rat H4IIE
Total Differentially Regulated
a Total Differentially Regulated
a Total Differentially Regulated
a
Unique Genes
b 6,995 624 8,478 438 5,169 56
Orthologs
c 6,825 616 8,233 432 4,871 52
a|fold change| > 1.4 and P1(t) > 0.999
bbased on Entrez GeneID
cbased on HomoloGeneID
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Figure 1 Number of TCDD-elicited differentially expressed
genes in human HepG2, mouse Hepa1c1c7 and rat H4IIE.
Global gene expression changes were detected using cDNA
microarray analysis of cells treated with 10 nM TCDD for 1, 2, 4, 8,
12, 24 and 48 hrs. Differentially expressed genes are defined as
having P1(t) > 0.999 and |fold change| > 1.4-fold at one or more
time points.
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Page 2 of 14TCDD, while responses that were attenuated or blocked
by CHX co-treatment were classified as secondary
responses based on their assumed dependence on addi-
tional protein translation. cDNA microarray analysis
confirmed the superinduction of CYP1A1 mRNA in
CHX co-treated Hepa1c1c7 cells [13,14], consistent with
the superinduction in human MCF10A cells treated
with TCDD [15]. Additionally, Hepa1c1c7 ARNT-defi-
cient c4 mutants treated with TCDD did not exhibit
induction of the prototypical AhR battery genes includ-
ing CYP1A1 [16]. Collectively, these results indicate that
CYP1A1 is a primary gene expression response consis-
tent with the direct interaction of the AhR with DREs
within the promoter region.
For each species, differentially expressed orthologs
were classified as primary or secondary responses based
on CHX co-treatment studies at both 4 and 12 hrs.
Overall 61, 38 and 2 human, mouse and rat orthologs,
respectively, were considered primary responses (Addi-
tional files 7, 8, 9). Furthermore, 45, 12 and 10 ortholo-
gous genes in the HepG2, Hepa1c1c7 and H4IIE cells
were classified as secondary AhR responses (Additional
files 10, 11, 12). Comparative examination of the CHX
co-treatment data suggested that each cell line had its
own unique set of primary responsive orthologs.
Whole-Genome Analysis of Conserved TCDD-Elicited Gene
Expression Responses
The lack of whole genome coverage on the human,
mouse and rat cDNA microarrays limited the number of
orthologs that could be investigated. Therefore, whole
genome expression analysis was performed at 24 hrs,
one of the most active time points in terms of the num-
ber of differentially expressed genes (Figure 1), using 4
× 44 k Agilent oligonucleotide microarrays. Each micro-
array contained more than 41,000 individual probes,
representing more than 18,000 unique genes (Table 2).
Despite the increased coverage, the number of TCDD
elicited differentially expressed genes were surprisingly
small relative to the cDNA microarray results. For
example, the human Agilent microarray consisted of
19,406 known genes, representing a 2.8-fold increase in
coverage compared to the human cDNA microarray.
However, only 899 unique genes were differentially
expressed, a modest increase from the 691 genes identi-
fied using cDNA microarrays. Similarly, only 519 and
121 genes were responsive in the Hepa1c1c7 and H4IIE
cells, respectively. Complete Agilent microarray data
sets are provided in Additional files 13, 14, 15.
The use of whole genome microarrays also increased
the number of orthologs that could be examined (Figure
5A). As seen with the cDNA microarray dataset pair-
wise comparisons, HepG2 and Hepa1c1c7 cells shared
the greatest number of TCDD responsive orthologs
(Additional files 16, 17, 18). Ortholog coverage between
all three species increased from 2252 on the cDNA
microarrays to 12,388 across the Agilent platforms.
Comparative analysis (P1(t) > 0.999 and |fold change| >
1.4) identified only 10 orthologs that were differentially
e x p r e s s e db yT C D Da t2 4h r s( F i g u r e5 B ;T a b l e3 ) .
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Figure 2 Hierarchical clustering of differentially expressed
genes (P1(t) > 0.999 and |fold change| > 1.4) from cDNA
microarray time course studies in HepG2, Hepa1c1c7 and H4IIE
hepatoma cells.
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Page 3 of 14Whole genome expression profiling identified the spe-
cies-conserved induction of CYP1A1, TIPARP and
UGT1A6 in all three cell lines. Despite this increased
coverage, the number of differentially expressed ortho-
logs across all three cell lines remained small, consistent
with our cDNA microarray results.
Species-Specific & Species-Divergent Gene Expression
Responses
Whole genome comparative analysis of HepG2,
Hepa1c1c7 and H4IIE responses identified genes that
were species-specific, i.e. differentially expressed in only
a single species. For example, microarray analysis at 24
hrs found that fibromodulin (FMOD, HomoloGene ID
1530) was significantly up-regulated 17.2-fold in the
HepG2 cells while no significant change in expression
was detected in the Hepa1c1c7 and H4IIE cells. Other
examples of mouse and rat specific responses include
forkhead box Q1 (FOXQ1, HomoloGene ID 7359) and
ectonucleoside triphosphate diphosphohydrolase 2
(ENTPD2, HomoloGene ID 20333). FOXQ1 was up-
regulated 5.9-fold in the Hepa1c1c7 cells while ENTPD2
was up-regulated 3.2-fold in the H4IIE cells. For both of
these genes, the corresponding ortholog in the other
two species did not exhibit significant differential
expression. The species-specific responses of FMOD,
FOXQ1 and ENTPD were verified using QRTPCR
(Figure 6). These responses are consistent with previous
reports of species-specific TCDD elicited hepatic gene
expression characterized in mice and rats [10,11].
Comparative analysis of the orthologous gene expres-
sion responses in HepG2, Hepa1c1c7 and H4IIE datasets
identified 10 orthologs that were differentially expressed
by TCDD across the three models. Further analysis indi-
cated that not all of these responses were directionally
conserved, i.e. pattern of expression was not the same in
all species. For example, IER3 was induced 1.4-fold in
Hepa1c1c7 cells at 4 hrs and 1.5-fold in H4IIE cells at
12 hrs, but repressed -1.9-fold in HepG2 cells at 24 hrs.
Likewise, glutathione S-transferase alpha 5 (GSTA5,
HomoloGene ID 74378) was induced 1.5-fold in
Hepa1c1c7 cells and 4.9-fold in H4IIE cells, but down-
regulated 2.5-fold in HepG2 cells. QRTPCR confirmed
the divergent expression of GSTA5 in the rat and
human cell lines, but found Hepa1c1c7 cells were
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Figure 3 Cross-species comparison of TCDD-elicited temporal gene expression responses using cDNA microarrays. (A) The lower half
(dark boxes) of the matrix show the number of orthologs represented between pairs of species-specific cDNA microarray platforms. The upper
half (grey boxes) of the matrix provides the number of TCDD elicited differentially expressed orthologs between pairs of cell lines. (B) The Venn
diagram shows the overlap of all differentially expressed genes (P1(t) > 0.999 and |fold change| > 1.4) from 2,252 possible orthologs represent
across all three microarray platforms. Additional files 4, 5, 6 lists the shared responses between pairs of species.
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Figure 4 QRTPCR verification of the conserved induction of
CYP1A1 across the human HepG2, mouse Hepa1c1c7 and rat
H4IIE cell lines. The same RNA used for microarray analysis was
examined by QRTPCR. Fold changes were calculated relative to
time-matched vehicle controls. Error bars represent the standard
error of measurement for the average fold change and the asterisk
(*) indicates p < 0.05.
Dere et al. BMC Genomics 2011, 12:193
http://www.biomedcentral.com/1471-2164/12/193
Page 4 of 14relatively non-responsive (Figure 7A). Two other ortho-
logs, cyclin D1 (CCND, HomoloGene ID 1334) and
inhibitor of DNA binding 3 (ID3, HomoloGene ID
1633), also exhibited divergent expression between spe-
cies, where the orthologs were down-regulated in the
rodent cell lines but induced in HepG2 cells (Table 3).
Species-specific and species-divergent responses have
also been reported in vivo for TCDD elicited hepatic dif-
ferential gene expression in mice and rats [10,11].
Functional Enrichment and Network Analysis
Microarray analysis identified a small subset of TCDD
responsive genes in the entire genome of each species.
Differentially expressed genes elicited by TCDD in each
cell line were clustered for functional enrichment based
on GO terms (enrichment score ≥ 1.5). Enriched
HepG2, Hepa1c1c7, and H4IIE responses clusters
included GO terms related to xenobiotic exposure
(GO:0009410) and metabolism (GO:0006805) (Tables 4,
5, 6), indicating that these processes are conserved in all
three cell lines, and consistent with reported in vivo stu-
dies using rats and mice[10-12]. However, other
enriched GO terms, such as those related to lipid
metabolism and transport, were only enriched in HepG2
and H4IIE cell lines. Genes functionally related to lipid
metabolism were further analyzed using Ingenuity Path-
way Analysis to identify a network of TCDD-responsive
orthologs, and species-conserved and -specific responses
(Figure 8). Although GO terms related to lipid metabo-
lism were enriched HepG2 and H4IIE differential gene
expression data sets, there were few orthologs that
exhibited differential regulation in both cell lines based
on the fold-change and statistical cutoffs used. In vivo
rat studies also identified enrichment of genes related to
lipid metabolism following TCDD treatment, suggesting
that H4IIE cells may be predictive of TCDD-induced
perturbations of this pathway rats.
Despite the nature of these continuous cell lines and
the dysregulation of genes related to cell cycle control
and regulation, GO terms associated with these func-
tions were not enriched across all three cell lines.
TCDD-treated Human HepG2 and mouse Hepa1c1c7
cell lines identified Functional clusters associated with
cell cycle control (GO:0022402) were in enriched
TCDD-treated HepG2 and Hepa1c1c7 gene expression
data sets, but not in the H4IIE data set. Species-
Table 2 Gene coverage of species-specific Agilent microarray platforms and number of differentially regulated genes
Human HepG2 Mouse Hepa1c1c7 Rat H4IIE
Total Differentially Regulated
a Total Differentially Regulated
a Total Differentially Regulated
a
Unique Genes
b 18,499 865 20,929 508 18,244 129
Orthologs
c 16,781 828 17,543 477 15,705 116
a|fold change| > 1.4 and P1(t) > 0.999
bbased on Entrez GeneID
cbased on HomoloGeneID
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Figure 5 Cross-species comparison of TCDD-elicited gene expression responses at 24 hrs using 4 × 44 k Agilent microarrays. (A) The
lower half (dark boxes) of the matrix show the number or orthologous genes represented between pairs of species-specific microarrays. The
upper half (grey boxes) provides the number of TCDD-elicited differentially expressed orthologs between pairs of cell lines. (B) The 3-way Venn
diagram shows the overlap of all differentially expressed genes (P1(t) > 0.999 and |fold change| > 1.4) from 12,388 possible orthologous genes
represented across all three platforms. The 9 genes differentially expressed in all three cell lines are listed in Table 3. Additional files 16, 17, 18
lists the shared responses between pairs of species.
Dere et al. BMC Genomics 2011, 12:193
http://www.biomedcentral.com/1471-2164/12/193
Page 5 of 14differences in functional clustering of TCDD-elicited dif-
ferentially expressed gene data sets further corroborate
species-specific responses to TCDD.
Dioxin Response Element Analysis
Putative functional DREs are not equally distributed
between species with more DREs associated with known
human genes [17,18]. Within the human genome, there are
213,355 DRE cores in the proximal promoter regions of
known genes (10kb upstream to 1kb downstream of a tran-
scriptional start site [TSS]), with 139,289 and 100,614 DRE
cores, in the mouse and rat genomes, respectively. To
further investigate the divergent expression of CCND1,
ID3 and GSTA5, their proximal promoter regions were
Table 3 List of common genes identified as differentially expressed by TCDD treatment from whole genome Agilent
microarray analysis
Gene Symbol Gene Name Homologene ID Fold change
a
Human Mouse Rat
NQO1 NAD(P)H dehydrogenase, quinone 1 695 3.22 ▲ 4.88 ▲ 4.82 ▲
CCND1 cyclin D1 1334 1.57 ▲ -1.56 ▼ -1.47 ▼
ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 1633 1.74 ▲ -1.83 ▼ -1.68 ▼
TIPARP TCDD-inducible poly(ADP-ribose) polymerase 9167 1.47 ▲ 7.05 ▲ 2.91 ▲
POC1A POC1 centriolar protein homolog A 51460 -1.64 ▼ -1.67 ▼ -1.57 ▼
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 68062 13.64 ▲ 153.52 ▲ 134.16 ▲
GSTA5 glutathione S-transferase A5 74378 -2.47 ▼ 1.47 ▲ 5.85 ▲
UGT1A6 UDP glucuronosyltransferase 1 family, polypeptide A6 85959 2.09 ▲ 2.24 ▲ 2.06 ▲
MT1E metallothionein 1E 108228 4.89 ▲ -1.66 ▼ 2.65 ▲
aMaximum absolute foldchange determined by microarray analysis
bDifferentially regulated genes with P1(t) > 0.999 and |foldchange| > 1.4
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Figure 6 QRTPCR verification of examples of species-specific orthologous gene expression responses identified from whole-genome
microarray analysis at 24 hrs in the human HepG2, mouse Hepa1c1c7 and rat H4IIE cell lines. The same RNA used for microarray analysis
was examined by QRTPCR. Representative orthologs that exhibited significant expression in only one species were verified; FMOD, ENTPD2 and
FOXQ1 and were differentially expressed in only the HepG2, Hepa1c1c7 and H4IIE cells respectively. Fold changes were calculated relative to
time-matched vehicle controls. Error bars represent the standard error of measurement for the average fold change and the asterisk (*) indicates
p < 0.05.
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Page 6 of 14searched for DRE cores. Human orthologs of CCND1 and
ID3 contained 12 and 14 DRE cores, respectively, greater
than the number found in either the mouse or rat gen-
omes. In contrast, mouse and rat orthologs of GSTA5 each
had 7 and 12 DRE cores, respectively, while the human
only had 3 (Figures 7B and 7C). In each of these diver-
gently regulated orthologs, the species with the greatest
number of DRE cores within the regulatory region had the
highest fold induction suggesting that species-specific regu-
lons have important roles in regulating gene expression.
Each DRE core in the GSTA5 orthologs was extended
by 7 bp on either end and assessed for sequence similarity
by measuring the Euclidean distance between sequence
pairs. Only the mouse and rat GSTA5 contained highly
similar DRE sequences (Euclidian distance of ≤ 3.0; shaded
rows in Figure 7C), and no human DRE sequences with
high sequence similarity. Furthermore, the position of the
conserved DRE sequence 5 bp upstream of the TSS in the
mouse appears to be positionally conserved with the DRE
sequence in rat the ortholog located 22 bp upstream of
the TSS. Collectively, the disproportionate number of
DREs between species and lack of sequence and spatially
conserved DREs may account for the divergent regulation
of human, mouse and rat GSTA5 orthologs.
Discussion
This study comprehensively and systematically compares
the gene expression responses elicited by TCDD across
human, mouse and rat cells. Incorporating both custom
cDNA microarrays to profile the temporal responses
and more comprehensive commercial oligonucleotide
microarrays, a limited number of conserved responses
between species were identified. In addition, divergent
and a large number of species-specific responses were
identified that may contribute to species-specific differ-
ences in sensitivity and toxicity. These results are con-
sistent with the poor response correlations of
orthologous genes between C57BL/6 mice, Sprague
Dawley and Long-Evans rats [10,11]. Collectively,
reported in vivo rodent comparisons, and the in vitro
data presented in this study suggest there are significant
differences in TCDD elicited gene expression between
species, despite the conservation of the AhR [4] and its
signaling pathway.
In vivo and in vitro studies examining TCDD-elicited
global gene expression have demonstrated that AhR tar-
gets a limited portion of the genome [10-12,19-23]. In
addition, PWM-based computational searches identified
a low percentage of orthologs with conserved putative
functional DREs within their regulatory regions (10kb
upstream of the TSS and the 5’UTR) [17,18]. Our com-
parative in vitro microarray results corroborate these
findings. Temporal analysis using custom cDNA micro-
arrays found that TCDD elicited a response in 9.9% of
the represented genes in the HepG2 cells, 5.2% in the
Hepa1c1c7 cells and only 1.1% in the H4IIE cells.
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mouse TACCCCTGCGTGGGATATG - -6901
GTACCAGGCGTGGTGGTGA + -6752
GAGTTGGGCGTGTCCACAG + -6551
TTGCCGTGCGTGCATCAAT + -6285
CTGCCGGGCGTGGTGGCGC - -2782
ATTAAAGGCGTGCGCCACC + -2771
center of the core DRE sequence relative to the TSS
GAAGGCAGCGTGAGTAGGT + -9223
AAGTGCCGCGTGCATGAAT - -9114
GGTCTCTGCGTGTAGGGAA + -8632
ATTCTGGGCGTGTTGTAGA + -8503
CTGAGGTGCGTGCAGTCTG - -7858
GGACTCAGCGTGACCACAG - -3871
TAACAAAGCGTGACTTTAA + -3169
CAGAGGAGCGTGCACGCCA + -2702
CTCTGCTGCGTGCCCAGTC + -1029
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Figure 7 Comparative analysis of GSTA5 orthologs. (A) QRTPCR verification of the divergent expression of GSTA5 orthologs in human HepG2,
mouse Hepa1c1c7 and rat H4IIE cell lines. Fold changes were calculated relative to time-matched vehicle controls. Error bars represent the
standard error of measurement for the average fold change and the asterisk (*) indicates p < 0.05. (B) Gene regulatory regions (-10,000 to 1,000
bp relative to the transcription start site [TSS]) were computationally searched for the 5 bp DRE core (GCGTC) and indicated by the grey boxes.
Each core was extended by the flanking 7 bp, and the resulting 19 bp sequence (C) was compared to a consensus DRE sequence using a
position weight matrix developed from bona fide functional DREs. The shaded rows in (C) indicate the highly similar mouse and rat DRE
sequences (Euclidean ≤ 3.0).
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Page 7 of 14Similar results were obtained using whole-genome
microarrays where 4.7%, 2.4% and 0.7% of the genes
exhibiting differential expression in HepG2, Hepa1c1c7
and H4IIE cells, respectively, at 24 hrs.
All three cell lines differentially expressed a core set of
conserved gene responses that included the induction of
CYP1A1, NQO1 and UGT1A6, members of the AhR
g e n eb a t t e r y[ 2 4 ] .H o w e v e r ,as i g n i f i c a n tn u m b e ro f
responses were specific to a single species (Figures 3B
and 3B), as reported in in vivo studies [10,11]. More-
over, these studies not only identified species-specific
responses, but also orthologs with divergent responses
(i.e. same gene up-regulated in one species and down-
regulated in other). Comparisons of C57BL/6 mouse
and Sprague Dawley rat responses found that 29% of
the commonly regulated orthologs exhibited divergent
regulation [11]. Similarly, GSTA5, CCND1 and ID3,
exhibited divergent regulation across HepG2, Hepa1c1c7
and H4IIE cells (Table 3). Each of these genes exhibited
the same pattern with Hepa1c1c7 and H4IIE cells hav-
ing comparable profiles while HepG2 cells exhibited the
divergent response. For example, GSTA5 was up-regu-
lated in Hepa1c1c7 and H4IIE cells, but down-regulated
in HepG2 cells (Table 3). In vivo gene expression
responses of GSTA5 orthologs matched the in vitro
responses in the Hepa1c1c7 and H4IIE cells; TCDD
treated mice and rats exhibited 1.8- and 1.9-fold maxi-
mum induction, respectively [11,12]. QRTPCR verified
Table 4 Functional enrichment analysis of differentially regulated
a genes elicited by TCDD in HepG2 cells using DAVID
Category Term Gene count Fold enrichment P-value
Enrichment Score: 2.99
GOTERM_BP_3 GO:0009410 ~ response to xenobiotic stimulus 10 8.03 1.54E-06
GOTERM_BP_3 GO:0006805 ~ xenobiotic metabolic process 9 8.32 4.92E-06
GOTERM_BP_3 GO:0017144 ~ drug metabolic process 3 3.46 2.13E-01
GOTERM_BP_3 GO:0006800 ~ oxygen and reactive oxygen species metabolic process 4 1.12 7.00E-01
Enrichment Score: 2.71
GOTERM_BP_3 GO:0022403 ~ cell cycle phase 40 1.80 4.36E-04
GOTERM_BP_3 GO:0048285 ~ organelle fission 25 2.03 1.35E-03
GOTERM_BP_3 GO:0000278 ~ mitotic cell cycle 34 1.70 3.07E-03
GOTERM_BP_3 GO:0022402 ~ cell cycle process 45 1.48 8.10E-03
Enrichment Score: 2.30
GOTERM_BP_3 GO:0006629 ~ lipid metabolic process 70 1.65 3.82E-05
GOTERM_BP_3 GO:0008610 ~ lipid biosynthetic process 25 1.47 5.48E-02
GOTERM_BP_3 GO:0044255 ~ cellular lipid metabolic process 37 1.34 6.10E-02
Enrichment Score: 2.03
GOTERM_BP_3 GO:0006790 ~ sulfur metabolic process 15 2.41 3.58E-03
GOTERM_BP_3 GO:0006518 ~ peptide metabolic process 9 3.20 6.37E-03
GOTERM_BP_3 GO:0051186 ~ cofactor metabolic process 20 1.91 8.81E-03
GOTERM_BP_3 GO:0006519 ~ cellular amino acid and derivative metabolic process 28 1.48 3.94E-02
Enrichment Score: 1.63
GOTERM_BP_3 GO:0005975 ~ carbohydrate metabolic process 43 1.55 4.51E-03
GOTERM_BP_3 GO:0044262 ~ cellular carbohydrate metabolic process 32 1.56 1.40E-02
GOTERM_BP_3 GO:0016051 ~ carbohydrate biosynthetic process 12 2.09 2.79E-02
GOTERM_BP_3 GO:0005996 ~ monosaccharide metabolic process 19 1.62 4.67E-02
GOTERM_BP_3 GO:0046165 ~ alcohol biosynthetic process 6 2.52 8.71E-02
Enrichment Score: 1.57
GOTERM_BP_3 GO:0010817 ~ regulation of hormone levels 17 2.11 6.67E-03
GOTERM_BP_3 GO:0034754 ~ cellular hormone metabolic process 9 2.87 1.22E-02
GOTERM_BP_3 GO:0042446 ~ hormone biosynthetic process 4 2.38 2.34E-01
aDifferentially regulated genes with P1(t) > 0.999 and |foldchange| > 1.4
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Page 8 of 14the divergent response of GSTA5 in the H4IIE and
HepG2 cells, but did not detect a significant induction
in the Hepa1c1c7 cells (Figure 7A).
Computational analysis of GST5A found a dispropor-
tionate number of DRE cores within the regulatory
region sequence of each species (Figure 7B and 7C).
Sequence analysis also found DRE sequences with high
similarity in the mouse and rat orthologs, but not in the
human GSTA5. The identification of species-specific
DREs is consistent with the divergent regulation of
GSTA5 between these cell lines. Overall, differences in
ortholog expression may contribute to differences in
TCDD sensitivity and toxicity across species.
Although these continuous cells lines are similar in
morphology and were derived from hepatomas, there
are inherent differences that may bias the identification
of species-conserved and -divergent responses. For
example, HepG2 cells were originally derived from the
liver biopsy of a 15-year old Caucasian male and there-
fore may not be representative of a mature adult liver
[25]. Recent studies have compared basal gene expres-
sion of liver samples to primary human hepatocytes,
HepG2 and HepaRG cells, another human hepatoma
cell line. Although, HepaRG cells were most similar to
primary hepatocytes and liver samples [26], toxicoge-
nomic studies report that HepaRG and HepG2 gene
expression responses retained common functional pro-
cesses [27]. In addition, the HepaRG donor differed in
age and sex compared to the HepG2 patient, and was
also infected with hepatitis C, which may affect both
basal and TCDD-elicited gene expression. HepG2 cells
were more sensitive in terms of the magnitude of regu-
lation, and also in the terms of the total number of dif-
ferentially regulated genes, and may be a more sensitive
model for assessing TCDD exposure [27].
Conclusion
Although a core set of conserved gene responses was
identified, consistent with the role of AhR in mediating
the adaptive metabolic responses, further evidence of
differences in genome-wide gene expression profiles
between species (i.e. species-specific regulons) is also
presented. This is consistent with species-specific differ-
ences in TCDD sensitivity and toxicity [6,8,28,29], which
are due to alterations in gene expression. Furthermore,
there is a lack of conserved putative DREs within ortho-
logous genes [18], and differences in genome-wide gene
expression profiles has been reported between mice and
rats in vivo [10,11]. Undoubtedly, the number of con-
served responses and immaturity of the genome annota-
tion, especially for the rat, limits the overall interspecies
comparison [30]. Differences in AhR levels, co-activator
availability, and protocols used in their isolation of these
hepatoma cells may confound our comparisons. Never-
theless, the identification of numerous species-specific
responses, evidence of divergent gene expression
Table 5 Functional enrichment analysis of differentially regulated
a genes elicited by TCDD in Hepa1c1c7 cells using
DAVID
Category Term Gene count Fold enrichment P-value
Enrichment Score: 18.67
GOTERM_BP_3 GO:0000278 ~ mitotic cell cycle 43 5.95 7.67E-21
GOTERM_BP_3 GO:0022402 ~ cell cycle process 52 4.50 1.15E-19
GOTERM_BP_3 GO:0022403 ~ cell cycle phase 47 4.87 3.67E-19
GOTERM_BP_3 GO:0048285 ~ organelle fission 36 6.14 6.31E-18
Enrichment Score: 2.05
GOTERM_BP_3 GO:0006805 ~ xenobiotic metabolic process 4 11.20 4.67E-03
GOTERM_BP_3 GO:0009410 ~ response to xenobiotic stimulus 4 8.96 9.05E-03
GOTERM_BP_3 GO:0006725 ~ cellular aromatic compound metabolic process 9 2.75 1.66E-02
Enrichment Score: 2.04
GOTERM_BP_3 GO:0048522 ~ positive regulation of cellular process 58 1.51 1.41E-03
GOTERM_BP_3 GO:0042127 ~ regulation of cell proliferation 27 1.72 7.62E-03
GOTERM_BP_3 GO:0008284 ~ positive regulation of cell proliferation 14 1.69 7.12E-02
Enrichment Score: 1.62
GOTERM_BP_3 GO:0051640 ~ organelle localization 7 4.36 5.10E-03
GOTERM_BP_3 GO:0051651 ~ maintenance of location in cell 4 5.38 3.68E-02
GOTERM_BP_3 GO:0051235 ~ maintenance of location 4 4.07 7.35E-02
aDifferentially regulated genes with P1(t) > 0.999 and |foldchange| > 1.4
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Page 9 of 14responses between species, and the discovery of distinct
putative primary response sets in each cell line provides
further compelling evidence that the effects of TCDD
post-AhR binding are not conserved between species.
Methods
Cell Culture and Treatment
HepG2 (Dr. Trevor Archer, NIEHS, Research Triangle
Park, NC), Hepa1c1c7 (Dr. Oliver Hankinson, University
of California, Los Angeles, CA), and H4IIE (Dr. Niels Bols,
University of Waterloo, Waterloo, Canada) cells were cul-
tured in monolayers and treated with TCDD (S. Safe,
Texas A&M University, College Station, TX) as previously
described [16]. Briefly, cells were treated with either 10 nM
TCDD or DMSO vehicle control for 1, 2, 4, 8, 12, 24 or 48
hrs for the time course studies. For co-treatment studies,
cells were pretreated with 10 mg/ml cycloheximide (CHX;
Sigma) for 1 hr and then treated for an additional 4 or 12
hrs with 10 nM TCDD or DMSO vehicle (Additional file
19). All treatment studies were performed in triplicate.
Table 6 Functional enrichment analysis of differentially regulated
a genes elicited by TCDD in H4IIE cells using DAVID
Category Term Gene count Fold enrichment P-value
Enrichment Score: 3.05
GOTERM_BP_3 GO:0006805 ~ xenobiotic metabolic process 7 34.21 3.52E-08
GOTERM_BP_3 GO:0009410 ~ response to xenobiotic stimulus 7 31.47 6.09E-08
GOTERM_BP_3 GO:0006725 ~ cellular aromatic compound metabolic process 6 5.07 6.28E-03
GOTERM_BP_3 GO:0017144 ~ drug metabolic process 3 16.86 1.31E-02
GOTERM_BP_3 GO:0051186 ~ cofactor metabolic process 6 3.61 2.44E-02
GOTERM_BP_3 GO:0046483 ~ heterocycle metabolic process 5 1.78 3.03E-01
GOTERM_BP_3 GO:0044248 ~ cellular catabolic process 8 1.39 3.41E-01
Enrichment Score: 2.45
GOTERM_BP_3 GO:0010035 ~ response to inorganic substance 11 4.70 1.00E-04
GOTERM_BP_3 GO:0006800 ~ oxygen and reactive oxygen species metabolic process 5 10.81 1.10E-03
GOTERM_BP_3 GO:0006979 ~ response to oxidative stress 7 4.50 4.38E-03
GOTERM_BP_3 GO:0044248 ~ cellular catabolic process 8 1.39 3.41E-01
Enrichment Score: 1.59
GOTERM_BP_3 GO:0006629 ~ lipid metabolic process 14 2.49 3.37E-03
GOTERM_BP_3 GO:0006082 ~ organic acid metabolic process 12 2.71 4.12E-03
GOTERM_BP_3 GO:0042180 ~ cellular ketone metabolic process 12 2.68 4.57E-03
GOTERM_BP_3 GO:0044255 ~ cellular lipid metabolic process 11 2.77 5.68E-03
GOTERM_BP_3 GO:0005996 ~ monosaccharide metabolic process 7 4.23 5.88E-03
GOTERM_BP_3 GO:0016051 ~ carbohydrate biosynthetic process 5 6.18 8.38E-03
GOTERM_BP_3 GO:0044262 ~ cellular carbohydrate metabolic process 7 2.63 4.80E-02
GOTERM_BP_3 GO:0046165 ~ alcohol biosynthetic process 3 8.03 5.25E-02
GOTERM_BP_3 GO:0005975 ~ carbohydrate metabolic process 8 2.25 6.22E-02
GOTERM_BP_3 GO:0006091 ~ generation of precursor metabolites and energy 5 2.70 1.11E-01
GOTERM_BP_3 GO:0008610 ~ lipid biosynthetic process 4 1.71 4.09E-01
GOTERM_BP_3 GO:0044249 ~ cellular biosynthetic process 16 1.04 5.74E-01
Enrichment Score: 1.58
GOTERM_BP_3 GO:0042493 ~ response to drug 11 3.94 4.20E-04
GOTERM_BP_3 GO:0006869 ~ lipid transport 4 3.91 8.07E-02
GOTERM_BP_3 GO:0010876 ~ lipid localization 4 3.54 1.01E-01
GOTERM_BP_3 GO:0042592 ~ homeostatic process 10 1.66 1.39E-01
Enrichment Score: 1.54
GOTERM_BP_3 GO:0044255 ~ cellular lipid metabolic process 11 2.77 5.68E-03
GOTERM_BP_3 GO:0006721 ~ terpenoid metabolic process 3 10.54 3.20E-02
GOTERM_BP_3 GO:0006766 ~ vitamin metabolic process 3 4.75 1.29E-01
aDifferentially regulated genes with P1(t) > 0.999 and |foldchange| > 1.4
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Page 10 of 14RNA Isolation
Cells were harvested with 2.0 mL of TRIzol
® Reagent
(Invitrogen) and total RNA isolated according to the
manufacturer’s protocol followed by an acid phenol:
chloroform extraction. Isolated RNA was resuspended in
The RNA Storage Solution (Ambion Inc., Austin, TX),
quantified (A260), and assessed for purity by measuring
the A260/A280 ratio and by visual inspection of 1.0 μgo n
a denaturing gel.
Microarray Experimental Design and Analysis
Gene expression changes were analyzed using custom
human, mouse and rat cDNA microarrays as previously
described [16,31,32]. Responses to CHX and TCDD co-
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Figure 8 Gene interaction network of TCDD-responsive orthologs functionally related to lipid metabolism. Molecules are represented by
nodes connected by arrows to indicate either direct or indirect relationships (dotted lines). Colors in the gene expression boxes represent the
direction and magnitude of the gene expression responses from the Agilent microarrays. The network visualizes species-conserved and
-divergent gene expression responses elicited by TCDD in the human HepG2, mouse Hepa1c1c7 and rat H4IIE cell lines.
Dere et al. BMC Genomics 2011, 12:193
http://www.biomedcentral.com/1471-2164/12/193
Page 11 of 14treatment were also assayed with cDNA microarrays
using a 2 × 2 factorial design (Additional file 20) [33].
Three replicates were performed with two independent
labelings per sample (dye swap). In total, 42 cDNA
microarrays were performed for each individual cell line.
Additionally, 4 × 44 k Agilent Technologies whole-gen-
ome oligonucleotide microarrays (Santa Clara, CA),
were used to profile the responses elicited by TCDD 24
hrs post-treatment according to the manufacturer’s
Two-Color Microarray-Based Gene Expression Analysis
protocol Version 5.0.1, including dye swap labelings.
Three replicates were performed for a total of 9 whole
genome microarrays for each cell line. Microarray data
quality was first assessed using a quality assurance pro-
tocol to ensure consistent high quality data throughout
all studies prior to normalization and further analysis
[34]. Microarray data were normalized using a semipara-
metric method [35], and statistically analyzed using an
empirical Bayes methods [36]. The data were hierarchi-
cally clustered using the Euclidian distance in Cluster
3.0 [37] and visualized with Java Treeview [38]. Func-
tional annotation clustering of Gene Ontology (GO)
terms for differentially expressed genes was performed
using DAVID (Database for Annotation, Visualization,
and Integrated Discovery) [39]. Annotation clusters with
an enrichment score ≥ 1.3 were considered significantly
enriched. Networks of direct and indirect molecular
interactions based on the whole-genome expression data
were identified and visualized using the Ingenuity Path-
way Analysis http://www.ingenuity.com.
Quantitative Real-Time PCR
The same total RNA samples isolated for microarray
studies were used for QRTPCR as previously described
[16]. The copy number of each unknown sample was
standardized to the geometric mean of three house-
keeping genes (b-actin, Gapd, Hprt or Rpl13). Official
gene names and symbols, RefSeq and Entrez Gene IDs,
forward and reverse primer sequences, and amplicon
sizes are provided in Additional file 21. Data were ana-
lyzed by analysis of variance (ANOVA) followed by
Tukey’s post hoc test using SAS 9.1 (SAS Institute, Cary,
NC). Differences between treatment groups were con-
sidered significant when p < 0.05.
Computational DREs Searches
The proximal promoter region (10 kb upstream and 1
kb downstream of a TSS) for a RefSeq corresponding to
an individual gene were computationally searched for
the substitute intolerant 5’-GCGTG-3’ DRE core
sequence and the position relative to the TSS were
determined using the center of the 5 bp core (under-
lined). Each core was then extended by 7 bp upstream
and downstream of the core to generate a 19 bp DRE
core containing sequence, which were assigned a matrix
similarity using a previously defined algorithm [18] and
with an updated position weight matrix [17]. The 19 bp
DRE core sequences from orthologous human, mouse
and rat genes were hierarchically clustered in R http://
www.R-project.org by measuring the Euclidean distance
between pairs of sequences. DRE sequences that clus-
tered together with a distance value ≤ 3.0 were charac-
terized as orthologous DREs.
Additional material
Additional File 1: HepG2 TCDD time course and cycloheximide
cotreatment cDNA microarray data. A table containing the expression
ratios relative to the time matched vehicle control for the time course
study. Ratios for the cycloheximide studies are relative to the treatment
condition. P1(t)-values represent posterior probabilities of activity on a
per gene and time-point basis or treatment condition using the model-
based t-value.
Additional File 2: Hepa1c1c7 TCDD time course and cycloheximide
cotreatment cDNA microarray data. A table containing the expression
ratios relative to the time matched vehicle control for the time course
study. Ratios for the cycloheximide studies are relative to the treatment
condition. P1(t)-values represent posterior probabilities of activity on a
per gene and time-point basis or treatment condition using the model-
based t-value.
Additional File 3: H4IIE TCDD time course and cycloheximide
cotreatment cDNA microarray data. A table containing the expression
ratios relative to the time matched vehicle control for the time course
study. Ratios for the cycloheximide studies are relative to the treatment
condition. P1(t)-values represent posterior probabilities of activity on a
per gene and time-point basis or treatment condition using the model-
based t-value.
Additional File 4: Common differentially regulated orthologs
elicited by TCDD in human HepG2 and mouse Hepa1c1c7 cells
identified from the cDNA microarray time course studies. A table
containing the expression ratios for significantly differentially regulated
orthologs (|fold change| > 1.4 and P1(t) > 0.999).
Additional File 5: Common differentially regulated orthologs
elicited by TCDD in rat H4IIE and mouse Hepa1c1c7 cells identified
from the cDNA microarray time course studies. A table containing
the expression ratios for significantly differentially regulated orthologs (|
fold change| > 1.4 and P1(t) > 0.999).
Additional File 6: Common differentially regulated orthologs
elicited by TCDD in human HepG2 and rat H4IIE cells identified
from the cDNA microarray time course studies. A table containing
the expression ratios for significantly differentially regulated orthologs (|
fold change| > 1.4 and P1(t) > 0.999).
Additional File 7: Putative human primary response genes and the
number of DREs in their promoters. A table listing the putative
primary response genes identified from the cycloheximide studies and
the number of 5’-GCGTG-3’ DRE cores in the region 10 kb upstream and
1 kb downstream of a TSS.
Additional File 8: Putative mouse primary response genes and the
number of DREs in their promoters. A table listing the putative
primary response genes identified from the cycloheximide studies and
the number of 5’-GCGTG-3’ DRE cores in the region 10 kb upstream and
1 kb downstream of a TSS.
Additional File 9: Putative rat primary response genes and the
number of DREs in their promoters. A table listing the putative
primary response genes identified from the cycloheximide studies and
the number of 5’-GCGTG-3’ DRE cores in the region 10 kb upstream and
1 kb downstream of a TSS.
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Page 12 of 14Additional File 10: Putative human secondary response genes and
the number of DREs in their promoters. A table listing the putative
secondary response genes identified from the cycloheximide studies and
the number of 5’-GCGTG-3’ DRE cores in the region 10 kb upstream and
1 kb downstream of a TSS.
Additional File 11: Putative mouse secondary response genes and
the number of DREs in their promoters. A table listing the putative
secondary response genes identified from the cycloheximide studies and
the number of 5’-GCGTG-3’ DRE cores in the region 10 kb upstream and
1 kb downstream of a TSS.
Additional File 12: Putative rat secondary response genes and the
number of DREs in their promoters. A table listing the putative
secondary response genes identified from the cycloheximide studies and
the number of 5’-GCGTG-3’ DRE cores in the region 10 kb upstream and
1 kb downstream of a TSS.
Additional File 13: Whole-genome Agilent microarray data from
HepG2 cells treated with TCDD for 24 hrs. A table containing the
expression ratio relative to the time matched vehicle control. P1(t)-values
represent posterior probabilities of activity on a per gene basis using the
model-based t-value.
Additional File 14: Whole-genome Agilent microarray data from
Hepa1c1c7 cells treated with TCDD for 24 hrs. A table containing the
expression ratio relative to the time matched vehicle control. P1(t)-values
represent posterior probabilities of activity on a per gene basis using the
model-based t-value.
Additional File 15: Whole-genome Agilent microarray data from
H4IIE cells treated with TCDD for 24 hrs. A table containing the
expression ratio relative to the time matched vehicle control. P1(t)-values
represent posterior probabilities of activity on a per gene basis using the
model-based t-value.
Additional File 16: Common differentially regulated orthologs
elicited by TCDD in human HepG2 and mouse Hepa1c1c7 cells
identified from the whole-genome Agilent microarrays at 24 hrs.A
table containing the expression ratios for significantly differentially
regulated orthologs (|fold change| > 1.4 and P1(t) > 0.999).
Additional File 17: Common differentially regulated orthologs
elicited by TCDD in rat H4IIE and mouse Hepa1c1c7 cells identified
from the whole-genome Agilent microarrays at 24 hrs. A table
containing the expression ratios for significantly differentially regulated
orthologs (|fold change| > 1.4 and P1(t) > 0.999).
Additional File 18: Common differentially regulated orthologs
elicited by TCDD in human HepG2 and rat H4IIE cells identified
from the whole-genome Agilent microarrays at 24 hrs. A table
containing the expression ratios for significantly differentially regulated
orthologs (|fold change| > 1.4 and P1(t) > 0.999).
Additional File 19: Cell culture TCDD treatment and harvesting
regimen. For the time course studies, cells were treated with 10 nM
TCDD or 0.1% DMSO vehicle and harvested at 1, 2, 4, 8, 12, 24, or 48 hrs
post-treatment. For the cycloheximide studies cells were treated with 10
mg/ml cycloheximide 1 hr and then treated with either 10 nM TCDD or
0.1% DMSO vehicle and for an additional 4 or 12 hrs (as indicated by *).
Additional File 20: 2 × 2 Factorial microarray experimental design
used for the cycloheximide expression studies. The hybridization
design used to identify putative primary and secondary gene expression
responses elicited by TCDD. Each arrow represents one microarray where
the arrow heads and tails refer to Cy5 and Cy3 dye labeling, respectively.
Double-headed arrows indicate dye swaps (each sample labeled with
Cy3 and Cy5 on different microarrays).
Additional File 21: Gene symbols and primer sequences for
QRTPCR. A list of genes and primer sequences used to verify cDNA and
Agilent microarray responses.
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